[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fNKp1ibVOXpbYbxi-xCQvZjsj1NaUqkzFjfZM3zYB2do":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":57,"rows":64},"The Hong Kong Polytechnic University",[4],613,false,200,1,82279,4,602,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Stroke",60,{"name":18,"count":19},"Myopia",34,{"name":21,"count":22},"Dementia",23,{"name":24,"count":25},"Depression",14,{"name":27,"count":28},"Healthy",12,{"name":30,"count":31},"Parkinson Disease",10,{"name":33,"count":34},"Insomnia",9,{"name":36,"count":34},"Electroencephalography",[38,43,48,53],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT05690737","Tai Chi for the Prophylaxis of Episodic Migraine: the Efficacy Examination and Mechanism Exploration","2025-12-31","Standard prophylactic medication",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT06358755","Combination Effect of Optical Defocus and Low Dose Atropine in Myopia Control","2026-05-30","Low dose atropine",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT06810817","Transcranial Direct Current Stimulation and Cognitive Behavioural Programme on Post-stroke Fatigue","2026-12","tDCS & cognitive behavioral programme with home-based physical training",{"nctId":54,"briefTitle":55,"date":51,"intervention":56},"NCT06282848","Pharmacological and Non-pharmacological Treatment Effects on Children With Different Predicted Myopia Progression Rate","Atropine 0.05%",[58,59,60,61,62,63],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[65,88,108,128,150,178,196,221,247,265,293,319,337,361,388,406],{"intervention":42,"totalTrials":9,"cells":66},{"EARLY_PHASE1":67,"PHASE1":70,"PHASE2":72,"PHASE3":74,"PHASE4":76,"NA":78},{"trials":68,"activeCount":69},[],0,{"trials":71,"activeCount":69},[],{"trials":73,"activeCount":69},[],{"trials":75,"activeCount":69},[],{"trials":77,"activeCount":69},[],{"trials":79,"activeCount":9,"soonestReadout":41},[80],{"nctId":39,"briefTitle":40,"status":81,"phases":82,"primaryCompletion":41,"completion":41,"start":83,"enrollment":84,"conditions":85,"interventions":87},"RECRUITING",[63],"2023-09-11",220,[86],"Migraine Disorders",[42],{"intervention":52,"totalTrials":9,"cells":89},{"EARLY_PHASE1":90,"PHASE1":92,"PHASE2":94,"PHASE3":96,"PHASE4":98,"NA":100},{"trials":91,"activeCount":69},[],{"trials":93,"activeCount":69},[],{"trials":95,"activeCount":69},[],{"trials":97,"activeCount":69},[],{"trials":99,"activeCount":69},[],{"trials":101,"activeCount":9,"soonestReadout":51},[102],{"nctId":49,"briefTitle":50,"status":81,"phases":103,"primaryCompletion":51,"completion":51,"start":104,"enrollment":105,"conditions":106,"interventions":107},[63],"2024-10-28",75,[15],[52],{"intervention":56,"totalTrials":9,"cells":109},{"EARLY_PHASE1":110,"PHASE1":112,"PHASE2":114,"PHASE3":116,"PHASE4":118,"NA":120},{"trials":111,"activeCount":69},[],{"trials":113,"activeCount":69},[],{"trials":115,"activeCount":69},[],{"trials":117,"activeCount":69},[],{"trials":119,"activeCount":69},[],{"trials":121,"activeCount":9,"soonestReadout":51},[122],{"nctId":54,"briefTitle":55,"status":81,"phases":123,"primaryCompletion":51,"completion":51,"start":124,"enrollment":125,"conditions":126,"interventions":127},[63],"2024-01-01",80,[18],[56],{"intervention":47,"totalTrials":9,"cells":129},{"EARLY_PHASE1":130,"PHASE1":132,"PHASE2":134,"PHASE3":136,"PHASE4":138,"NA":140},{"trials":131,"activeCount":69},[],{"trials":133,"activeCount":69},[],{"trials":135,"activeCount":69},[],{"trials":137,"activeCount":69},[],{"trials":139,"activeCount":69},[],{"trials":141,"activeCount":9,"soonestReadout":46},[142],{"nctId":44,"briefTitle":45,"status":143,"phases":144,"primaryCompletion":46,"completion":145,"start":146,"enrollment":147,"conditions":148,"interventions":149},"ACTIVE_NOT_RECRUITING",[63],"2027-01-31","2024-07-12",112,[18],[47],{"intervention":151,"totalTrials":9,"cells":152},"Cure-Allergic Rhinitis Syrup",{"EARLY_PHASE1":153,"PHASE1":155,"PHASE2":157,"PHASE3":172,"PHASE4":174,"NA":176},{"trials":154,"activeCount":69},[],{"trials":156,"activeCount":69},[],{"trials":158,"activeCount":69},[159],{"nctId":160,"briefTitle":161,"status":162,"phases":163,"primaryCompletion":164,"completion":165,"start":166,"enrollment":167,"conditions":168,"interventions":170},"NCT02027194","Controlled Trial of Chinese Herbal Medicine to Treat Allergic Rhinitis","COMPLETED",[59,60],"2014-08","2014-10","2012-06",298,[169],"Allergic Rhinitis",[151,171],"Yu-ping-fung San",{"trials":173,"activeCount":69},[],{"trials":175,"activeCount":69},[],{"trials":177,"activeCount":69},[],{"intervention":171,"totalTrials":9,"cells":179},{"EARLY_PHASE1":180,"PHASE1":182,"PHASE2":184,"PHASE3":190,"PHASE4":192,"NA":194},{"trials":181,"activeCount":69},[],{"trials":183,"activeCount":69},[],{"trials":185,"activeCount":69},[186],{"nctId":160,"briefTitle":161,"status":162,"phases":187,"primaryCompletion":164,"completion":165,"start":166,"enrollment":167,"conditions":188,"interventions":189},[59,60],[169],[151,171],{"trials":191,"activeCount":69},[],{"trials":193,"activeCount":69},[],{"trials":195,"activeCount":69},[],{"intervention":197,"totalTrials":9,"cells":198},"Systane COMPLETE Lubricant Eye Drops",{"EARLY_PHASE1":199,"PHASE1":201,"PHASE2":203,"PHASE3":215,"PHASE4":217,"NA":219},{"trials":200,"activeCount":69},[],{"trials":202,"activeCount":69},[],{"trials":204,"activeCount":69},[205],{"nctId":206,"briefTitle":207,"status":162,"phases":208,"primaryCompletion":209,"completion":209,"start":210,"enrollment":211,"conditions":212,"interventions":214},"NCT06188260","Efficacy of a New Nanoemulsion Artificial Tear Targeting Dry Eye Disease",[60],"2024-11-04","2024-01-16",31,[213],"Dry Eye Syndromes",[197],{"trials":216,"activeCount":69},[],{"trials":218,"activeCount":69},[],{"trials":220,"activeCount":69},[],{"intervention":222,"totalTrials":9,"cells":223},"JUC solution",{"EARLY_PHASE1":224,"PHASE1":226,"PHASE2":228,"PHASE3":241,"PHASE4":243,"NA":245},{"trials":225,"activeCount":69},[],{"trials":227,"activeCount":69},[],{"trials":229,"activeCount":69},[230],{"nctId":231,"briefTitle":232,"status":162,"phases":233,"primaryCompletion":234,"completion":235,"start":166,"enrollment":236,"conditions":237,"interventions":239},"NCT01824888","Efficacy of JUC as Hand Rub Evaluated by Using European Standard 1500",[60],"2012-08","2012-12",15,[238],"Infectious Disease Transmission",[222,240],"propan-2-ol",{"trials":242,"activeCount":69},[],{"trials":244,"activeCount":69},[],{"trials":246,"activeCount":69},[],{"intervention":240,"totalTrials":9,"cells":248},{"EARLY_PHASE1":249,"PHASE1":251,"PHASE2":253,"PHASE3":259,"PHASE4":261,"NA":263},{"trials":250,"activeCount":69},[],{"trials":252,"activeCount":69},[],{"trials":254,"activeCount":69},[255],{"nctId":231,"briefTitle":232,"status":162,"phases":256,"primaryCompletion":234,"completion":235,"start":166,"enrollment":236,"conditions":257,"interventions":258},[60],[238],[222,240],{"trials":260,"activeCount":69},[],{"trials":262,"activeCount":69},[],{"trials":264,"activeCount":69},[],{"intervention":266,"totalTrials":9,"cells":267},"Standard anti-emetic treatment",{"EARLY_PHASE1":268,"PHASE1":270,"PHASE2":272,"PHASE3":274,"PHASE4":276,"NA":278},{"trials":269,"activeCount":69},[],{"trials":271,"activeCount":69},[],{"trials":273,"activeCount":69},[],{"trials":275,"activeCount":69},[],{"trials":277,"activeCount":69},[],{"trials":279,"activeCount":69},[280],{"nctId":281,"briefTitle":282,"status":162,"phases":283,"primaryCompletion":284,"completion":285,"start":286,"enrollment":287,"conditions":288,"interventions":292},"NCT02403037","Auricular Acupressure for Chemotherapy-Induced Nausea and Vomiting in Female Breast Cancer Patients",[63],"2016-09","2016-10","2015-07",114,[289,290,291],"Breast Neoplasms","Nausea","Vomiting",[266],{"intervention":294,"totalTrials":9,"cells":295},"Atropine",{"EARLY_PHASE1":296,"PHASE1":298,"PHASE2":300,"PHASE3":302,"PHASE4":304,"NA":306},{"trials":297,"activeCount":69},[],{"trials":299,"activeCount":69},[],{"trials":301,"activeCount":69},[],{"trials":303,"activeCount":69},[],{"trials":305,"activeCount":69},[],{"trials":307,"activeCount":69},[308],{"nctId":309,"briefTitle":310,"status":162,"phases":311,"primaryCompletion":312,"completion":313,"start":314,"enrollment":315,"conditions":316,"interventions":317},"NCT03374306","Topical Application of Low-concentration (0.01%) Atropine on the Human Eye With Fast and Slow Myopia Progression Rate",[63],"2019-12-31","2020-08-31","2018-02-01",71,[18],[294,318],"Artificial tear",{"intervention":318,"totalTrials":9,"cells":320},{"EARLY_PHASE1":321,"PHASE1":323,"PHASE2":325,"PHASE3":327,"PHASE4":329,"NA":331},{"trials":322,"activeCount":69},[],{"trials":324,"activeCount":69},[],{"trials":326,"activeCount":69},[],{"trials":328,"activeCount":69},[],{"trials":330,"activeCount":69},[],{"trials":332,"activeCount":69},[333],{"nctId":309,"briefTitle":310,"status":162,"phases":334,"primaryCompletion":312,"completion":313,"start":314,"enrollment":315,"conditions":335,"interventions":336},[63],[18],[294,318],{"intervention":338,"totalTrials":9,"cells":339},"0.01% atropine eye drops",{"EARLY_PHASE1":340,"PHASE1":342,"PHASE2":344,"PHASE3":346,"PHASE4":348,"NA":350},{"trials":341,"activeCount":69},[],{"trials":343,"activeCount":69},[],{"trials":345,"activeCount":69},[],{"trials":347,"activeCount":69},[],{"trials":349,"activeCount":69},[],{"trials":351,"activeCount":69},[352],{"nctId":353,"briefTitle":354,"status":162,"phases":355,"primaryCompletion":356,"completion":356,"start":357,"enrollment":358,"conditions":359,"interventions":360},"NCT02955927","Combined Atropine With Orthokeratology in Childhood Myopia Control (AOK) -A Randomized Controlled Trial",[63],"2021-05-08","2016-11",89,[18],[338],{"intervention":362,"totalTrials":9,"cells":363},"PNS+AO+Training",{"EARLY_PHASE1":364,"PHASE1":366,"PHASE2":368,"PHASE3":370,"PHASE4":372,"NA":374},{"trials":365,"activeCount":69},[],{"trials":367,"activeCount":69},[],{"trials":369,"activeCount":69},[],{"trials":371,"activeCount":69},[],{"trials":373,"activeCount":69},[],{"trials":375,"activeCount":69},[376],{"nctId":377,"briefTitle":378,"status":162,"phases":379,"primaryCompletion":380,"completion":381,"start":382,"enrollment":383,"conditions":384,"interventions":385},"NCT03625804","The Cortical Motor Effects of PNS and AO on Motor Training in Chronic Stroke",[63],"2015-06-01","2015-06-30","2014-06-23",20,[15],[362,386,387],"PNS+AOsham+Training","PNSsham+AOsham+Training",{"intervention":386,"totalTrials":9,"cells":389},{"EARLY_PHASE1":390,"PHASE1":392,"PHASE2":394,"PHASE3":396,"PHASE4":398,"NA":400},{"trials":391,"activeCount":69},[],{"trials":393,"activeCount":69},[],{"trials":395,"activeCount":69},[],{"trials":397,"activeCount":69},[],{"trials":399,"activeCount":69},[],{"trials":401,"activeCount":69},[402],{"nctId":377,"briefTitle":378,"status":162,"phases":403,"primaryCompletion":380,"completion":381,"start":382,"enrollment":383,"conditions":404,"interventions":405},[63],[15],[362,386,387],{"intervention":387,"totalTrials":9,"cells":407},{"EARLY_PHASE1":408,"PHASE1":410,"PHASE2":412,"PHASE3":414,"PHASE4":416,"NA":418},{"trials":409,"activeCount":69},[],{"trials":411,"activeCount":69},[],{"trials":413,"activeCount":69},[],{"trials":415,"activeCount":69},[],{"trials":417,"activeCount":69},[],{"trials":419,"activeCount":69},[420],{"nctId":377,"briefTitle":378,"status":162,"phases":421,"primaryCompletion":380,"completion":381,"start":382,"enrollment":383,"conditions":422,"interventions":423},[63],[15],[362,386,387]]